Skip to main content
Category

Article

Bimekizumab approved in Europe for Psoriasis treatment

Bimekizumab (Bimzelx), a humanized IgG1 monoclonal antibody, is the first approved treatment for moderate to severe plaque psoriasis that selectively inhibits interleukin (IL)–17A and IL-17F.

Dose: 320 mg, given in two subcutaneous injections every 4 weeks to week 16, then every 8 weeks.

Adverse effects: Upper respiratory tract infections (a majority of which were nasopharyngitis), reported by 14.5% of patients, followed by oral candidiasis, reported by 7.3%.

Bimekizumab is contraindicated for individuals with clinically important active infections such as tuberculosis, and for individuals with any hypersensitivity to the active substance.

Source: MDedge

FDA has expanded indication for the noninvasive Deep TMSTM

The US Food and Drug Administration (FDA) has expanded indication for the noninvasive BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMSTM) System to include treatment of comorbid anxiety symptoms in adult patients with depression, the company has announced. The neurostimulation system has previously received FDA approval for treatment-resistant major depression, obsessive-compulsive disorder, and smoking addiction.

Source: Medscape

Microscopic lung damage may continue in ‘Long COVID’

The persistent breathing issues that plague some COVID-19 survivors, known as ‘long COVID,’ may be due to microscopic processes that continue to damage lungs even after the acute infection is over, new findings suggest. Researchers studied blood and bronchoalveolar fluid samples from 38 patients who still had breathing problems at least three months after they were discharged from hospital.

Source: Medrxiv.org

A new monoclonal antibody named CIS43LS prevents malaria in new trial

A new monoclonal antibody discovered and developed at the National Institutes of Health safely prevented malaria for up to 9 months in people who were exposed to the malaria parasite. The small clinical trial is the first to show an antibody capable of preventing malaria in people. A total of 25 participants received at least one dose of an antibody named CIS43LS, and four of them received a second dose. Among adults who had never had malaria infection or vaccination, CIS43LS prevented malaria.

Source: NEJM

Icotinib is the best adjuvant chemotherapy for EGFR-mutant NSCLC

Icotinib is a highly selective, first-generation EGFR tyrosine kinase inhibitor (TKI) approved in China as first-line monotherapy in patients with NSCLC with somatic EGFR mutations. Following complete resection of EGFR-mutant stage-II to -IIIA non-small-cell lung cancer (NSCLC), icotinib significantly improves disease-free survival and has fewer side effects than chemotherapy, according to interim results of a phase-3 trial underway in China.

Source: The Lancet Respiratory Medicine

Physicians wearing white coats rated more experienced

Physicians wearing white coats were rated as significantly more experienced and professional than peers wearing casual attire. Regardless of their attire, however, female physicians were more likely to be judged as appearing less professional and were more likely to be misidentified as medical technicians, physician assistants, or nurses, found research published in JAMA Network Open.

A white coat with scrubs attire was most preferred for surgeons (mean preference index, 1.3), whereas a white coat with business attire was preferred for family physicians and dermatologists (mean preference indexes, 1.6 and 1.2, respectively; P < .001.

While casual attire, such as fleece or softshell jackets emblazoned with the names of the institution and wearer, has become more popular attire for physicians in recent years.

Source: JAMA Network

New guideline for replacement of ART: CAB/RPV LA not for everyone

Approved by the FDA in late January 2021, CAB/RPV LA (cabotegravir/rilpivirine) is considered an optimization strategy for individuals with HIV whose virus is suppressed by oral ART and who might prefer monthly injections versus daily oral therapy. While there are various reasons why patients might wish to switch to a long-acting injectable, one of the primary concerns is adherence. Of note, the guidance points to phase 3 clinical study findings that suggest high levels (86% to 91%) of patient satisfaction with CAB/RPV LA, which portends a promising future for this therapeutic approach.

With regard to patient preference, recommendations focus on the need to thoroughly discuss several critical requisites with potential candidates, including a 4-week lead-in daily oral ART course (CAB [Vocabria] 30 mg, RPV [Edurant] 25 mg) before initiating a loading dose. Patients should be advised of the potential for development of resistance should dosing be interrupted for any reason (CAB and RPV have extended half-lives ranging from mean 5.6-11.5 weeks for CAB and 13-28 weeks for RPV), as well as the need to return to oral bridging therapy if subsequent injections are not administered within the 7-day window period. If the maintenance dose is delayed beyond 2 months, a loading dose and restart is necessary.

CAB/RPV LA therapy is administered into opposing gluteal muscles (CAB into one gluteus medius and RPV into the contralateral gluteus medius) and injection-site pain beginning 1 day post-injection and lasting 3-4 days is common.

Source: Medscape

Restoring pulmonary endothelial cells reverses emphysema in mice

Correcting endothelial dysfunction in both human tissue and an elastase-induced murine model of emphysema shows promise in stopping and reversing the course of the disease, according to an international group of researchers.

EC loss and dysfunction were also hallmarks of emphysematous lungs harvested from the elastase-treated mice. The team found that intravenous delivery of healthy lung ECs from genetically identical mice reversed these phenotypes.

“We also found,” continued Dr. Racanelli, “that removing a specific molecule from the cells had a similar result.” In particular the researchers observe that “Leucine-rich a-2-glycoprotein- 1 (LRG1) was a driver of emphysema, and deletion of Lrg1 from endothelial cells rescued vascular rarefaction and alveolar regression.” LRG1 upregulation, they note ,”directly correlated with severity of the COPD phenotype.”

Source: Journal of Experimental Medicine

New investigational helmet device shrinks glioblastoma

A case report describes a novel helmet device that generates a noninvasive oscillating magnetic field and that shrunk a glioblastoma tumor by about a third.

The patient had end-stage recurrent glioblastoma and had undergone all standard therapy options. He wore the device for 5 weeks but died from an unrelated injury, so the treatment period was cut short.

A brain scan showed a 31% reduction of contrast-enhanced tumor volume, and an autopsy of his brain confirmed the rapid response to the treatment.

Source: Frontiers in Oncology

Delta variant of COVID-19 as contagious as chickenpox

Internal Centers for Disease Control and Prevention (CDC) documents support the high transmission rate of the delta variant and put the risk in easier to understand terms. The documents also show that breakthrough infections in the vaccinated make people about as contagious as those who are unvaccinated. In addition to being more transmissible, the delta variant likely causes more severe COVID-19 illness.

Source: Medscape

error: